Genedrive Regulatory News (GDR)

31 Jul 2007 07:01

EpiStem Holdings plc31 July 2007 EPISTEM HOLDINGS PLC TRADING UPDATE - JULY 2007 The Board Of Directors of EpiStem Holdings Plc confirm that the results for theCompany for the year ended 30th June 2007 are in line with managementexpectations with a year on year revenue growth of approximately 50% beingachieved. Further details of the financial performance for the year will beannounced in October 2007 (to be confirmed). The Board of Directors is also pleased to announce the appointment of RogerLloyd as a non-executive Director of the Company. Dr Lloyd, aged 59, brings awealth of experience to EpiStem, having only recently stood down as ExecutiveDirector, Global Licensing at AstraZeneca plc. In this capacity, he headed upthe deal making team responsible for the acquisitions by AstraZeneca ofCambridge Antibody Technologies plc and KuDOS Pharmaceuticals Limited as well asother strategically important transactions. This information is provided by RNS The company news service from the London Stock Exchange